Track market-moving stories before they get noisy

By PYMNTS  |  June 26, 2026

 | 

Amazon and Walmart are spending this week is summer sale mode. Amazon’s four-day Prime Day runs June 23 through June 26, while Walmart Deals started a day earlier and ends two days later. U.S. online spending across retailers reached $8.3 billion on Prime Day’s first day, up 5.3% from a year earlier, Adobe Analytics said. But the discounts are the visible skirmish. The more consequential contest is over who owns the advertisement, the screen and the data trail that lead to a purchase.

Walmart’s agreement to buy French advertising startup Vibe.co, reported by The Wall Street Journal at $1.4 billion, turns its $2.3 billion Vizio acquisition in 2024 into more than a hardware bet. Vizio gives Walmart a place to show advertising in the living room. Vibe brings self-service software that lets smaller businesses buy connected-television ads. Walmart Connect supplies shopper data and the ability to compare ad exposure with purchases online and in stores. Think of Walmart as trying to own not only the shopping mall, but also the television station, billboard company and cash register inside it.

Advertising lets a retailer earn more from a customer relationship without carrying more inventory. Walmart’s global ad business grew 46% to nearly $6.4 billion in fiscal 2026 and another 37% in its latest quarter. Amazon’s advertising business, however, exceeded $70 billion over the latest 12 months, the eCommerce giant said in its latest earnings report. The gap remains vast, but Walmart’s growth and acquisitions show that it wants advertising to become a central profit engine rather than a side business.

Shoppable television is an important bridge. Instead of seeing a patio set during a program and searching for it later, a viewer can move toward a purchase from the screen, while the retailer can tell the brand whether the ad produced a sale. Independent analyst Andrew Lipsman called the overlap between retail media and connected television “a mega story in 2026.” NScreenMedia analyst Colin Dixon put the value more directly: “Definitive attribution makes the ads far more valuable to brands.”

Walmart has begun demonstrating the model. “Backyard Escapes,” a Vizio program hosted by Tan France, built supplier products into makeover content and directed viewers toward Walmart’s patio-and-garden assortment. Walmart said the value of merchandise sold during the related event was nearly 40% higher than a year earlier, digital sales increased more than 50%, and nearly half of purchasers were new to the category. Those are Walmart’s figures, not an independent audit, but they show the pitch: entertainment that also behaves like a storefront.

Amazon already operates a more mature version of that system. Prime Video, Fire TV and Amazon’s shopping data lets viewers add products to a cart from their television. In May, Amazon introduced Dynamic TV Creative, which changes an ad’s product details and call to action according to a viewer’s shopping behavior. Amazon said its interactive video formats generate four times as many add-to-cart actions and five times the purchase rate of standard streaming-TV campaigns. Those figures, too, are company-reported.

Vibe is Walmart’s attempt to broaden that opportunity beyond large advertisers. Its software is designed to let smaller companies, including Walmart marketplace sellers, launch television campaigns without a large agency or media-buying staff. That could bring more advertising demand to Vizio’s screens and give Walmart more campaign data with which to improve its system.

The implications extend beyond advertising. More ad profit could help either retailer invest in prices, delivery and membership benefits, intensifying the shopping competition. Consumers may get more relevant offers, but also more commercial messages in places once reserved for entertainment. If every home-improvement show starts to feel like an infomercial, the model will lose some of its appeal.

Amazon still owns the larger machine. Walmart’s moves show it is no longer merely matching Prime Day discounts. It is trying to control the path from inspiration on a television to a basket online or in a store. The sale events are the fireworks. The advertising infrastructure is the power grid, and Walmart has just spent heavily to build one.

Moderna (MRNA 1.03%) has been on fire this year. As of this writing, the company's shares have slightly more than doubled to date. What's more, the biotech has an important catalyst on the horizon. Let's find out whether there is any upside left for the company.

Image source: Getty Images.

Racing toward an approval Moderna has been working on an influenza vaccine, mRNA-1010. It submitted regulatory applications for this candidate earlier this year. The U.S. Food and Drug Administration (FDA) should approve or reject Moderna's application by Aug. 5. It's an important date for the biotech company, as an approval in this field might allow it to establish itself as a leader in the flu market. True, plenty of flu vaccines exist, but their efficacy is usually not very impressive, typically between 40% to 60% in the U.S. In phase 3 studies, mRNA-1010 performed better than approved vaccines in patients aged 50 and older who tend to be more at risk of severe cases of the disease, hospitalization, and death.

And if there was any doubt about whether mRNA-1010 would get the FDA's green light, recent developments have made that outcome practically certain. Members of an advisory committee convened by the FDA to give their opinion on whether mRNA-1010 should earn approval unanimously voted in favor. The health regulatory agency doesn't always follow the advice of these experts, but it almost always does. It would be surprising if mRNA-1010 doesn't get the nod.

Today's Change

(

-1.03

%) $

-0.62

Current Price

$

59.80

What does this mean for the stock? Moderna's shares soared after the advisory committee's vote of confidence for mRNA-1010. So, it's likely the market has already priced in a positive outcome, and the stock won't move much once mRNA-1010 is approved. However, there are still good reasons to invest in Moderna. The company is once again demonstrating its innovative qualities with mRNA-1010, just as it did with its coronavirus vaccine, which became a leader in that niche. The flu vaccine market isn't that large. According to some estimates, it was worth $8.9 billion last year, although it will continue growing at a good clip for the foreseeable future. Moderna's potential sales in this niche alone do not justify its $24.5 billion market cap, especially given that it generates meager revenue from its currently approved products.

That said, the vaccine maker has a rich pipeline with several products that could become key growth drivers. For instance, Moderna is developing mRNA-4157, an investigational personalized cancer vaccine that has shown highly encouraging clinical trial results and is now undergoing several phase 2 and phase 3 studies. Moderna is also going after difficult targets. The company is developing an HIV vaccine. Moderna's success in the flu vaccine market will help it pursue even more lucrative markets. Over the next five years, the company could have a much broader portfolio of approved products while generating strong revenue and earnings. That's why Moderna's shares are still attractive, even after climbing by about 100% this year.

Many investors are chasing after artificial intelligence (AI)-focused companies that have already gained substantial market value this year. That's not a bad strategy, considering the AI industry may maintain its momentum for a while and reward these leaders even more. However, it's also important for investors to consider companies that haven't performed well recently. There may be opportunities to pick up attractive stocks on the dip. In fact, here are two great examples: Netflix (NFLX 1.29%) and Shopify (SHOP 2.45%). Here is why these companies are worth investing in right now.

Image source: The Motley Fool.

1. Netflix Netflix stock recently hit a 52-week low. A poor second-quarter guidance and the departure of Reed Hastings -- who will no longer have any role at the company after co-founding and helping lead it as its co-CEO for a long time, and being a member of the board for the past few years -- are spooking investors. However, now that the stock has declined by 43% over the past 12 months, Netflix's shares look very attractive. Let's consider four reasons why. First, it's not uncommon for Netflix's shares to drop significantly after earnings. But the company tends to rebound. Investing in Netflix's stock after a major sell-off has generally been an excellent idea.

True, the past is no guarantee of future performance, but Netflix's business still has what it takes to perform well. Which brings us to our second point: Netflix's position in streaming remains strong, even though competition has intensified significantly since the turn of the decade. But Netflix has adapted. It offers multiple subscription options to cater to customers of all types, including price-sensitive ones. It also boasts a deep user base whose viewing habits and preferences help it craft its strong content strategy. That's why Netflix continues to attract new members. As of the end of 2025, the company had over 325 million paid subscriptions.

Today's Change

(

-1.29

%) $

-0.93

Current Price

$

70.92

There is a good chance that number will keep climbing, given Netflix's network effect: The more users on its platform, the more data it has access to, which helps it determine which shows and movies to create or license. The result is an even better content library and even more paying members. Third, Netflix still has attractive opportunities in streaming, notably by making further headway into market niches it does not currently dominate but are very lucrative. That's what it's been doing in the realm of sports streaming. It may take a while for Netflix to gain a foothold there, but if it can, that will help boost the company's sales and earnings over the long run.

Lastly, Netflix is increasingly leveraging technological advances, including AI. For instance, it launched a feed of short, TikTok-style videos personalized to each user's preferences, powered by an AI-based recommendation algorithm designed to help users find new shows. Initiatives like this may help boost engagement. Netflix still has ample white space in the streaming industry, and the company is well-positioned to capitalize on it over the long run. That makes it a top stock to buy on the dip.

2. Shopify Shopify has suffered the same fate as many other software companies this year. Many investors believe that AI will replace their services and are exiting the industry in droves. It also doesn't help that Shopify's valuation looks steep. Even after losing 27% of its value this year, Shopify is trading at 61 times forward earnings, versus an average of 22.4 for information technology stocks. That said, when focusing on Shopify's underlying business, things seem to be going just fine. In the first quarter, the company's revenue rose 34% year over year to $3.2 billion.

Shopify's revenue growth rate accelerated versus the first quarter of 2025, when it posted year over year sales increase of 27%. Also, although the company wasn't profitable, its net loss of $581 million was better than the loss of $682 million reported in the year-ago period. And, aside from the impact of the company's equity investments -- a better gauge of profits from day-to-day operations -- Shopify posted a net income of $360 million, 59% higher than the year-ago period.

Today's Change

(

-2.45

%) $

-2.80

Current Price

$

111.37

Meanwhile, the company's free cash flow jumped 31% year over year to $476 million, while its free cash flow margin held steady at a healthy 15%. Shopify's second-quarter guidance was slightly disappointing: it expects year-over-year top-line growth in the high twenties. Even so, the company is performing well and is actually incorporating AI into its services to enhance clients' experience. That's the thing: AI may not replace software companies at all. It might, instead, help them offer even better products to their customers. Shopify has launched several AI-powered services, including a store builder that does the job in minutes.

Further, the company still boasts a strong competitive advantage thanks to switching costs, as well as a long runway for growth in the e-commerce industry, which remains in high-growth mode. Shopify should grow into its valuation over the long run as it capitalizes on the massive opportunities ahead.

The ChatGPT developer is inclined to delay its initial public offering until 2027, according to a report.

Here are three stocks with buy rank and strong income characteristics for investors to consider today, June 26:

LyondellBasell Industries N.V. (LYB - Free Report) : This chemical company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 60.5% over the last 60 days.

This Zacks Rank #1 company has a dividend yield of 4.9%, compared with the industry average of 1.6%.

Localiza Rent a Car (LZRFY - Free Report) : This car rental business from Brazil has witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.3% over the last 60 days.

This Zacks Rank #1 company has a dividend yield of 4.5%, compared with the industry average of 1.1%.

Standard Chartered PLC (SCBFY - Free Report) : This banking company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.9% over the last 60 days.

This Zacks Rank #1 company has a dividend yield of 3.4%, compared with the industry average of 2.7%.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Find more top income stocks with some of our great premium screens.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Most drivers replace their vehicles the same way: make payments for a few years, trade the car in, then start the cycle over again. A portfolio can break that cycle by generating enough income to fund future replacements. With the average new vehicle now costing roughly $48,000 to $49,000 and inflation continuing to push prices higher, every replacement is likely to cost more than the last. The question is simple: how much capital would it take to buy your next car, and the one after that, without ever signing another loan agreement?

Never Have A Car Payment Again A vehicle payment is one of the few bills people willingly renew every few years. The average new auto loan now extends beyond six years, meaning many drivers trade one payment for another before the first obligation is even far behind them. Funding a replacement vehicle through portfolio income changes the equation. Instead of committing to a recurring payment schedule, you create a stream of cash that can be used whenever a replacement is needed. Buy a new car this year, wait another three years, or drive the current one for a decade. The income continues arriving either way. The longer you postpone the purchase, the more time that income has to accumulate and compound. Flexibility, not just transportation, is what the portfolio is really buying.

Three Budgets, Four Yields Assume a trade-in covers part of each replacement. Three realistic annual budgets: $10,000 (a $30,000 car every three years), $15,000 (a $45,000 car), and $25,000 (a $75,000 car). Divide the budget by the yield to get the capital required.

Annual Need 3.5% yield 5% yield 7% yield 10% yield $10,000 ($833/mo) $285,714 $200,000 $142,857 $100,000 $15,000 ($1,250/mo) $428,571 $300,000 $214,286 $150,000 $25,000 ($2,083/mo) $714,286 $500,000 $357,143 $250,000 The 3.5% column is the dividend-growth tier: blue-chip equities with rising payouts. The 5% to 7% columns are utilities, net-lease REITs, and midstream MLPs. The 10% column is BDCs, mortgage REITs, and leveraged covered-call funds, where principal often erodes.

The 3.5% Grower Versus The 10% Payer Take the $15,000 case. Portfolio A starts at $428,571 yielding 3.5% with 7% annual dividend growth. Portfolio B starts at $150,000 yielding 10% flat. Year one, both produce $15,000. Year ten, Portfolio A pays roughly $29,500 while Portfolio B still pays $15,000, and high-yield principal often shrinks. Year twenty, Portfolio A throws off close to $58,000, enough to upgrade the vehicle class. Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) illustrates the engine: 64 consecutive years of increases, with the quarterly payout moving from $1.06 in 2022 to $1.34 in 2026. P&G (NYSE:PG) just notched its 70th annual hike.

Depreciation Is The Hidden Hurdle A replacement vehicle is a moving target. New cars typically lose substantial value in their first few years on the road, while the cost of buying the next one keeps rising. Maintenance expenses also tend to accelerate as vehicles age and warranties expire. Meanwhile, inflation steadily pushes sticker prices higher. A portfolio generating a flat $15,000 a year may cover today’s replacement budget but struggle to keep pace with tomorrow’s. A growing income stream has a better chance of matching rising vehicle costs and preserving purchasing power over the decades.

Filling The Middle Tiers Between the grower and the high-yield payer sits the workhorse income tier. Duke Energy (NYSE:DUK) yields roughly 3.4% with mid-single-digit hike history. Realty Income (NYSE:O) pays monthly at about 5.2% and has now logged hundreds of consecutive monthly dividends. Enterprise Products Partners (NYSE:EPD) yields about 6% on a $2.20 annualized distribution. Beyond these, investment-grade corporate bonds, preferred shares from large banks, and 10-year Treasuries near 4% round out the menu without resorting to leveraged products.

When Keeping The Old Car Wins From a purely financial perspective, driving a vehicle longer is usually the better move. Many wealthy people, including Sam Walton, were known for driving older vehicles, and Dave Ramsey has long argued that keeping cars longer is one of the easiest ways to build wealth. For retirees who drive relatively few miles, the replacement cycle itself can be more expensive than the financing.

Still, retirement is about funding the lifestyle you want. For retirees with substantial portfolios, a newer vehicle can mean fewer repairs, less downtime, warranty coverage, and greater peace of mind. This portfolio is not about finding the cheapest transportation. It is about determining what it takes to afford a new vehicle every few years without disrupting the rest of your retirement plan.

What To Do This Week Decide your actual replacement budget after trade-in, then divide by a yield you can defend without leverage. Compare ten-year total return on a 157% appreciation name like JNJ against a flat-NAV 10% fund before committing capital. If you are within five years of retirement, model the tax bracket impact of qualified dividends versus MLP K-1 income in your state.

BlackBerry Ltd. reported a stronger first quarter, posting higher profit and revenue compared with the same period last year while increasing its revenue outlook for the full fiscal year.

The software company, which reports its financial results in US dollars, recorded a net profit of $8.5 million for the three months ended May 31, 2026, compared with $1.9 million in the corresponding quarter a year earlier.

Revenue for the quarter rose 26 per cent to $152.9 million, up from $121.7 million in the same period last year.

Investors responded positively to the results.

Following the release of its first-quarter results, BlackBerry's shares climbed 16% on the Toronto Stock Exchange on Thursday.

At the time of writing, the stock was up about 0.39% in pre-market trading.

Following the quarterly performance, BlackBerry raised its revenue guidance for the full fiscal year.

The company now expects annual revenue to be between $594 million and $621 million, compared with its previous forecast of $584 million to $611 million.

BlackBerry reported earnings of one US cent per share for the quarter, compared with break-even results in the same period last year.

The company earned four US cents per share, up from two US cents per share a year earlier.

Management said the interim consolidated financial statements were prepared in accordance with United States generally accepted accounting principles.

The company noted that the statements do not include all disclosures required for annual financial reporting and should be read alongside its audited annual financial statements for the year ended February 28, 2026.

Management also stated that all normal recurring adjustments considered necessary for a fair presentation have been included.

However, it cautioned that operating results for the quarter ended May 31, 2026, may not necessarily indicate performance for the full fiscal year ending February 28, 2027.

The company added that preparing the financial statements requires management to make estimates and assumptions related to assets, liabilities, revenue, expenses, and contingent liabilities.

Actual results could differ from those estimates, and the differences could be material.

Operating structure remains unchangedBlackBerry said it continues to operate through three reportable business segments: QNX, Secure Communications, and Licensing.

The company also said there were no material changes to its significant accounting policies or critical accounting estimates compared with those outlined in its annual financial statements.

BB said it adopted ASU 2025-05 during the first quarter of fiscal 2027.

The accounting update relates to the estimation of expected credit losses on certain receivables.

According to the company, adopting the standard did not have, and is not expected to have, a material impact on its consolidated financial statements.

The company also outlined several accounting standards that have not yet been adopted.

BlackBerry said it plans to adopt ASU 2024-03 in fiscal 2028 and is evaluating its disclosure requirements.

It also expects to adopt ASU 2025-09, covering derivatives and hedge accounting, in fiscal 2028.

The company said it has not yet determined the potential impact of the guidance on its financial statements.

The company said it measures fair value based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.

BlackBerry stated that it uses a three-level fair value hierarchy based on observable and unobservable inputs.

Cash, cash equivalents, receivables, and accounts payable are carried at amounts that approximate their fair values because of their short-term nature.

The company said it primarily relies on an independent third-party valuator to determine the fair value of investments while conducting its own internal review of pricing for reasonableness.

It also remeasures certain long-lived assets and non-marketable equity investments when events indicate impairment or other valuation changes.

Team Internet Group PLC (AIM:TIG, OTCQX:TIGXF, FRA:4CN), which earns recurring revenue from powering online identity and discovery, said its year of transition was complete as it set its sights firmly on growth in 2026.

Publishing its audited results for 2025, chief executive Michael Riedl said the group had reshaped itself and strengthened its financing through amended facilities and extended maturities, with its growth segments carrying real momentum into the new year.

The company expressed confidence in meeting market expectations for 2026.

Much of the year gone was defined by a deliberate shift towards higher-quality, more durable revenue across its three divisions rather than chasing headline volume.

The clearest transformation came in its Search segment, where next-generation monetisation formats grew to account for 39% of segment revenue, up from under 5% a year earlier, as the business moved away from older advertising models.

Its domains division strengthened its long-duration earnings by securing a ten-year contract to run the .co registry, while benefits from the integration of recent acquisition Unity fed through to margins.

International expansion also accelerated, with the comparison division delivering its first positive contributions in France, Italy and Spain and launching a UK portal.

Gross merchandise value generated outside its core German-speaking markets rose more than tenfold to 4.8% of the total.

The financial figures, which were broadly flagged in a trading update on 15 June, reflected the cost of that transition.

Gross revenue fell to $481.9 million from $802.8 million, while adjusted earnings before interest, tax, depreciation and amortisation more than halved to $42.7 million.

The group swung to an operating loss of $49.9 million after taking $41.7 million of impairment charges against its Search segment, leaving a loss after tax of $62.5 million.

Despite the downturn, gross margin widened to 28.3% from 23.4% and the business remained strongly cash generative, cutting net debt by $8.8 million to $87.6 million even after shareholder distributions.

Leverage rose to 2.9 times adjusted earnings, up from 1.2 times, reflecting the weaker profit during the transition.

Wise PLC (LSE:WISE, FRA:6WS) reported a sharp rise in profit and customer activity in the 2026 financial year and unveiled plans for a new share buyback worth at least $500 million.

The money transfer and payments company said income before tax rose to $660.4 million, giving it a margin of 26%, ahead of its medium-term target range. Net revenue increased 19% to $2.5 billion, at the top end of its long-term growth target.

Growth was driven by a 21% increase in active customers to 18.9 million and a 31% rise in cross-border volumes to $243.5 billion.

The company also continued to expand beyond international transfers. Customer holdings rose 40% to $39 billion, while spending on Wise cards increased 37% to $43.6 billion.

Chief executive and co-founder Kristo Käärmann said: "These investments helped us drive even better customer outcomes and support 19 million people and businesses move $243 billion across the world last year."

During the year, Wise added direct connections to payment systems in Brazil and Japan, secured new licences in South Africa, the UAE and Thailand, and signed new platform partnerships including UniCredit and Raiffeisen Bank.

Wise said it expected net revenue growth in the 2027 financial year to be around the middle of its 15-20% medium-term target range, with its income before tax margin around the top end of its 20-25% guidance range.

June 26, 2026 2:48 AM 1 min read

Apogee Enterprises, Synaptics And 3 Stocks To Watch Heading Into FridayWith U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Check out our premarket coverage here

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Posted In:

Trading IdeasPre-Market OutlookLong IdeasNewsEarningsStocks To Watch

If you've been reading Motley Fool articles on Elon Musk's company, Space Exploration Technologies (SPCX 1.00%), or SpaceX, you've probably seen more than a few of my colleagues deem the stock overvalued. Stock analysts at Morningstar see the stock similarly.

In fact, Morningstar estimates that the stock is trading at a 152% premium. It placed a fair value of $62 on the stock as of June 16, which is well above the $154 closing price as of June 24. That price gives the company a market capitalization of $2.05 trillion. If the price were $62, the corresponding market cap would be around $800 billion -- still a hefty sum. The difference between the two valuations is a whopping $1.2 trillion.

Image source: Getty Images.

So who's right? See what you think.

Valuing SpaceX You might want to check SpaceX's price-to-earnings (P/E) ratio, but you can't -- because there are no earnings. The company is currently losing money, and a lot of it. In such situations, though, you can check out the price-to-sales ratio, which uses the business's revenue instead of earnings. In SpaceX's case, its recent price-to-sales ratio was 78 (as of June 24). That's a steep number.

Today's Change

(

-1.00

%) $

-1.54

Current Price

$

153.00

To appreciate the magnitude of SpaceX's price-to-sales ratio, think of one of the most high-flying stocks in recent years -- semiconductor giant Nvidia. It has averaged annual gains of 67% over the past decade and is up nearly 40% over the past year. Yet its price-to-sales ratio is just 19. Even more striking is memory giant Micron, whose shares have soared 762% over the past year. Its price-to-sales ratio is 20.5 (again, as of June 24). You can see how much more investors are willing to pay for a dollar of SpaceX's sales, versus other highly regarded tech companies.

Who's right? No one can say for sure which valuation is correct -- or closer to correct. Every analyst's valuation is always based on various assumptions about growth rates and other factors. But it's hard to not see SpaceX's shares as richly valued, and a closer look at the stock will reveal multiple reasons why you might want to steer clear.

After all, it's still not turning a profit. In 2025, it lost nearly $5 billion. While its Starlink business, featuring satellite-based internet, is profitable, its growth appears to be slowing, with shrinking revenue per user.

Anyone investing now is expecting the stock to go up, but it's been going down lately -- down 22.6% over the past week, as of June 23. Remember that should there be a market pullback, growth stocks and overvalued stocks tend to fall harder than average. So there's clearly risk in this investment.

The $62-per-share valuation seems more appropriate to me than a $155 one. If you don't agree with me, wait for the company's upcoming earnings report, expected in a month or so, to see how it's doing.

When a big-name stock executes a stock split, it gets a lot of attention. That's because stock splits are considered bullish indicators -- the company is splitting its stock to make it more affordable to retail investors. It also provides the company with greater flexibility in offering compensation packages that include stock equity for its employees. It's a win-win, generally.

That's why the 3-for-1 stock split that Tesla (TSLA 0.28%) announced in August 2022 got so much attention. Tesla was a high-flying stock, gaining 2,000% in the three years immediately before the split. Had you invested $10,000 into Tesla in August 2019, you would have had $210,000 the day of the split.

But against those lofty expectations, Tesla stock has been a disappointment since the split. It's gained only 28% since executing the split on Aug. 25, 2022, meaning that had you invested $10,000 in Tesla the day before the split, you'd only have $12,800. Meanwhile, the S&P 500 (^GSPC 0.01%) gained 77% over the same period, and a $10,000 investment in an S&P 500 index fund, such as the Vanguard 500 Index Fund ETF (VOO +0.00%), would have grown to nearly $17,800.

TSLA data by YCharts

Tesla, before and after the split Before the stock split, Tesla was riding high. The adoption of electric vehicles was in full force, and Tesla saw impressive growth as it expanded both domestically and overseas.

For example, when Tesla reported second-quarter earnings in 2022, the company hit $1 billion in quarterly net income for the first time. It posted revenue of $11.96 billion and earnings of $1.45 per share, beating analysts' expectations of $11.30 billion and $0.98 per share, respectively. It was a massive win for Tesla, which saw its net income rise from $438 million to $1.14 billion in a single quarter.

Today's Change

(

-0.28

%) $

-1.04

Current Price

$

374.49

Perhaps most importantly, Tesla's profit margins remained exceptionally high, at 28.4%.

But Tesla today is a very different company. Competition is fierce. Margins are down. And CEO Elon Musk got involved in both U.S. and European politics, which damaged the Tesla brand. A Yale University report estimates that Musk's political activities resulted in more than 1 million fewer Tesla sales. Tesla saw annual declines in automotive sales in both 2024 and 2025.

Image source: Tesla.

Tesla's revenues in the first quarter of this year were $19.3 billion, up 16% from a year ago. But even with that bright spot, Tesla's net income was just $47.7 million. The company hasn't seen $1 billion in quarterly net income since the fourth quarter of 2024.

Tesla is undergoing significant change today. The company is still an EV maker, but it's also investing heavily in Musk's vision for its Optimus robot line that he hopes to make available to both consumers and factories. Tesla continues to work on its full self-driving technology in hopes of securing approval for unsupervised, nationwide use. But both ventures are speculative and expensive.

The company's shrinking profitability explains why a $10,000 investment made before the stock split has dramatically underperformed both investors' expectations and the broader market.

Item 1 of 2 A man walks by the logo of Microsoft in a shop of Brussels September 17, 2007. Microsoft suffered a stunning defeat on Monday when a European Union court backed a European Commission ruling that the U.S. software giant illegally abused its market power to crush competitors. This logo has been updated and is no longer in use. REUTERS/Sebastien Pirlet (BELGIUM)

[1/2]A man walks by the logo of Microsoft in a shop of Brussels September 17, 2007. Microsoft suffered a stunning defeat on Monday when a European Union court backed a European Commission ruling that... Purchase Licensing Rights, opens new tab Read more

CompaniesROME, June 26 (Reuters) - Italy's antitrust authority said on Friday it ​had opened an investigation ‌into Microsoft (MSFT.O), opens new tab over alleged unfair commercial practices linked to the ​price hike of its "Microsoft ​365" subscription.

The regulator said the ⁠Windows maker did not ​adequately inform consumers that its ​Microsoft 365 service had been integrated with artificial intelligence tools Copilot ​and Designer.

The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.

Consumers were automatically ​moved to a more expensive subscription plan ‌unless ⁠they actively opted out, while receiving insufficient information to decide whether to renew ​their contracts, ​the ⁠watchdog added in its statement.

It added that ​the tech giant's practice ​could ⁠be considered aggressive because it unduly limited consumers' freedom ⁠of ​choice.

Microsoft was ​not immediately available for comment.

Reporting by Giulia ​Segreti, editing by Alvise Armellini

Our Standards: The Thomson Reuters Trust Principles., opens new tab

SAN FRANCISCO--(BUSINESS WIRE)--Visa (NYSE: V), a global leader in digital payments, today announced the launch of Visa Destinations, a passion-led travel platform live in 10 major locations around the world, as the company redefines its role in the rapidly growing experience-driven travel economy.

The move marks a strategic expansion of Visa’s role beyond payments, positioning the company at the center of how travelers discover, plan and experience trips. According to Visa research, travelers are increasingly choosing destinations based on passion, purpose, and experiences, not just geography. In 2025 alone, 4 in 10 American travelers made a trip to experience music, sports or art festivals1, with major cultural moments acting as magnets for international visitors and catalysts for local economies.

Available exclusively to Visa customers, through a mobile-first platform, Visa Destinations is designed around why people travel, whether they are drawn by food, fashion, sports or simply wandering the streets for hidden gems, it delivers tastemaker recommendations, city guides, and curated experiences to support Visa’s shift from being the way to pay for travel to becoming a travel companion.

“Travel is expected to grow 10% annually over the coming years2. It consistently shows resilience to the world’s events and consumers protect it. Our latest Visa Global Travel Intentions Study indicates customers will cut back on everyday spending to save for planned travel,” said Katya Petelina, Head of Global Cross-Border and Global Sales & Commercial Operations at Visa. “With Visa Destinations, we are accompanying travelers throughout their journey and helping them discover the moments that make a destination memorable, while giving our issuers and merchant partners a meaningful way to participate in the economic growth that travel creates.”

Visa Destinations is available and curating experiences in 10 locations, including Paris, London, Dubai, Milan, Rome, Mexico City, New York City, Miami, San Francisco and Thailand.

Once on board, cardholders can enhance their trips through curated offerings across dining, entertainment, culture, hospitality, wellness, shopping and transport, such as exclusive viewing moments and Priority Access to Top of the Rock Observation Deck at Rockefeller Center in New York City and the Louvre in Paris, as well as dining experiences tastemakers recommend.

Premium cardholders, including Visa Infinite and Visa Signature, can enjoy enhanced benefits and tailored travel experiences.

Strong partnerships behind Visa Destinations

Visa has partnered with global leaders across the financial and travel ecosystem to increase the platform’s value proposition. Global anchor partners include financial institution Santander Group, promoting Visa Destinations to their customers in key regions around the world, and travel partners Global Blue, Star Alliance, and Trip.com Group. Together, these partnerships provide Visa cardholders with exclusive access, premium benefits, and locally distinctive experiences that bring cardholders closer to the character of each destination.

“At Santander, we believe travel is about creating meaningful memories and discovering unique experiences that connect people with destinations,” said Matías Sánchez, Global Head of Cards and Digital Solutions at Santander. “Through our partnership with Visa, we are bringing exclusive opportunities to our customers across ten key markets, giving them access to extraordinary experiences in music, sports, fashion, gastronomy and culture that can only be enjoyed through this global collaboration.” "We are delighted to partner with Visa to bring the value of the Tax Free Shopping experience to travelers using Visa Destinations. In doing so, international travelers benefit from increased purchasing power, a seamless and guaranteed refund process, and an enhanced shopping journey while immersing themselves in the destination of their choice," said Virginie Alem, Global Blue Chief Marketing Officer. “As the leading global airline alliance, Star Alliance is uniquely positioned to offer travelers access to unmatched reach through our 26 member airlines, enabling seamless multi-airline journeys. This partnership with Visa will deliver great value to travelers through exclusive experiences that will make every journey even more memorable. We are excited about the opportunities this collaboration will unlock,” said Renato Ramos, Vice President Corporate Strategy, Star Alliance. “Travel should always be inspiring, intuitive, and rewarding. That is why at Trip.com Group, we are constantly reimagining how journeys are planned and experienced – with simplicity at every touch point. Our collaboration with Visa brings this vision to life, combining secure, seamless payments with curated travel offerings and elevated benefits, turning every journey into something truly extraordinary,” said Sun Bo, Chief Marketing Officer at Trip.com Group. Beyond serving travellers, Visa Destinations supports Visa’s broader strategy to deepen digital commerce, enable seamless cross-border payments, and help travel-related businesses capture greater value from global tourism.

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

1 Visa’s Global Travel Intentions Study 2026
2 Boston Consulting Group

More News From Visa Inc.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In First Solar To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in First Solar between February 26, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against First Solar, Inc. ("First Solar" or the "Company") (NASDAQ: FSLR) and reminds investors of the August 24, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants had overstated First Solar's capacity to manage the impact of U.S. tariff policy on the Company's business; (2) Defendants understated the extent to which its responses to U.S. tariff policy, including the intentional underutilization of production facilities in Malaysia and Vietnam, and attempted relocation of production to the U.S., were likely to negatively impact First Solar's projected performance in the 2026 fiscal year; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The truth began to emerge on January 7, 2026, when Jefferies downgraded First Solar to Hold from Buy, noting that during 2025, the Company had lowered guidance, faced significant de-bookings and experienced margin compression through 2025. Jefferies also flagged that "[international] facilities remain a pain point while tariffs exist" and "underutilization at [international] facilities remains a concern." The Jefferies analyst also predicted that First Solar's deployment opportunities were likely to be more limited in 2026.

On this news, First Solar's stock price fell $27.67 per share, or 10.29%, to close at $241.11 per share on January 7, 2026.

Then, on February 24, 2026, First Solar issued a press release "announc[ing] financial results for the fourth quarter and year ended December 31, 2025." Among other items, First Solar announced earnings that missed expectations by a wide margin and issued lower-than-expected FY 2026 revenue guidance, citing customer headwinds such as permitting delays under the Trump administration. Following First Solar's announcement, Baird Research downgraded its stock to Neutral from Outperform, citing "several question marks in forward outlook".

On this news, First Solar's stock price fell $33.09 per share, or 13.61%, to close at $210.12 per share on February 25, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding First Solar's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the First Solar, Inc. class action, go to www.faruqilaw.com/FSLR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the First Solar, Inc. Securities Class Action Lawsuit:

What is the First Solar securities fraud lawsuit about?

The lawsuit alleges that First Solar, Inc. and certain executives violated federal securities laws by making false or misleading statements and failing to disclose material information regarding the impact of U.S. tariff policies, production facility utilization, and risks to the Company's projected 2026 financial performance.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired First Solar (NASDAQ: FSLR) securities during the applicable Class Period and suffered losses may be eligible to participate in the securities class action. Eligibility will depend on the specific circumstances of each investor's transactions and losses.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation. Any eligible investor may seek appointment as lead plaintiff by filing the appropriate motion with the court on or before the August 24, 2026 deadline.

What should investors do if they purchased First Solar stock during the Class Period?

Investors who purchased First Solar securities during the Class Period and experienced losses should review their legal rights and options. They may contact counsel to discuss the lawsuit, determine whether they qualify to participate, and learn more about seeking appointment as lead plaintiff before the applicable deadline.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased First Solar securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients beginning July 1

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced additional details regarding the Medicare GLP-1 Bridge* program taking effect July 1, 2026. Under the program, Medicare Part D patients may be able to access Foundayo (orforglipron) or Zepbound (tirzepatide) KwikPen for single-patient-use for weight management. The Medicare GLP-1 Bridge program will be the first time eligible Medicare Part D patients will be able to broadly receive coverage for a GLP-1 for overweight or obesity.1 We believe this is a milestone that reflects growing recognition of the impact of obesity, including in older adults. Below is what patients and their healthcare providers need to know, including an overview of the clinical and program eligibility requirements determined by Centers for Medicare & Medicaid Services (CMS).

Are Foundayo (orforglipron) and Zepbound (tirzepatide) covered by Medicare through the GLP-1 Bridge program?
Medicare Part D patients who meet the Medicare GLP-1 Bridge Clinical Criteria and other CMS eligibility requirements may be able to access Foundayo (orforglipron) or Zepbound (tirzepatide) for weight management under the Medicare GLP-1 Bridge program for $50 per month. Other weight management medications are also covered under the program. Coverage begins July 1, 2026, for new and existing patients and will run through December 31, 2027.

Foundayo (orforglipron) and Zepbound (tirzepatide) are indicated for adults with obesity, or some adults with overweight who also have weight-related medical problems, along with a reduced calorie diet and increased physical activity.

To learn more, visit www.lilly.com/lillydirect/medicare. For questions about the Medicare GLP-1 Bridge program, refer to https://www.medicare.gov/coverage/weight-loss-drugs.

Why is this a milestone for people on Medicare living with obesity?
Until now, weight management medications have not been broadly covered by Medicare even though two in five U.S. adults aged 65 and older are living with obesity.2 Creating a Medicare Part D coverage pathway for eligible patients advances Lilly's long-held view of obesity as a chronic disease. It also unlocks access to Lilly's obesity medicines, offering patients and their doctors options rather than a one-size-fits-all approach.

"Lilly estimates that approximately 20 million Medicare patients may meet clinical criteria for obesity medicines, and starting July 1, eligible patients will be able to get Zepbound or Foundayo for $50 per month," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. "For many, this will be the first time obesity treatment has been within reach. We're proud to offer Foundayo and Zepbound, giving patients and their doctors a real choice between a daily pill that requires no planning around food or drink and the number 1 most prescribed injectable for weight loss.3 Both are proven to deliver meaningful weight loss when paired with a reduced calorie diet and increased physical activity."

How much do Foundayo (orforglipron) and Zepbound (tirzepatide) cost through the program?
Medicare Part D patients may be eligible for Foundayo or Zepbound for weight management for $50 a month, with a prior authorization and if they meet the Medicare GLP-1 Bridge Clinical Criteria and other CMS eligibility requirements. To learn more, visit www.lilly.com/lillydirect/medicare.

What are Foundayo (orforglipron) and Zepbound (tirzepatide)?
Foundayo (orforglipron) and Zepbound (tirzepatide) are two different Lilly medicines for chronic weight management, giving patients and their healthcare providers a choice of treatment options. Foundayo is a once-daily oral pill that can be taken any time of day, with no planning around food or drink. Zepbound is the most prescribed injectable weight management medication in the U.S. Both are FDA-approved to help adults with obesity, or some adults with overweight who also have weight-related medical problems, lose excess body weight and keep it off, along with a reduced-calorie diet and increased physical activity.

How do Foundayo (orforglipron) and Zepbound (tirzepatide) work in adults age 65 and older? 
In separate analyses of Phase 3 trials, both medicines were associated with meaningful weight loss in adults 65 and older, with safety profiles generally consistent with the overall study population. In a post-hoc analysis of ATTAIN-1, adults 65 and older without type 2 diabetes, experienced an average weight loss of 13% when taking the highest dose of Foundayo. In the ATTAIN program, Foundayo also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure in adults of all ages.6

In a separate 72-week Phase 3 study, SURMOUNT-1, 56.7% of adults of all ages without type 2 diabetes taking Zepbound (15 mg) achieved at least 20% body weight reduction.7 In a prespecified subgroup analysis of this study, adults 65 and older without type 2 diabetes lost an average of 14.1% of their body weight when taking the lowest approved maintenance dose of Zepbound (5 mg), which is only one step up from the starter dose.8

"Obesity is a chronic, complex disease that deserves effective, long-term treatment options at every stage of life," said Rachel Batterham, senior vice president for Global Cardiometabolic Health at Lilly. "Data show Lilly's Foundayo and Zepbound were associated with meaningful weight loss in people aged 65 and older, with safety profiles generally consistent with other age groups, reinforcing that these medicines may be effective and appropriate for older adults."

Who is eligible for these medicines through the Medicare GLP-1 Bridge program?
To qualify, a person must meet all of the Medicare GLP-1 Bridge Clinical Criteria and other CMS eligibility requirements when treatment is started:9

Be 18 years of age or older Have Medicare Part D drug coverage (not all plan types are covered)† Have a valid prescription, be using, or planning to use, Foundayo or Zepbound for weight management, alongside lifestyle modification consistent with the FDA approved labels Have a Body Mass Index (BMI) of 35 or higher, or a BMI of 27 or higher with certain weight-related medical conditions (or have had one before starting a GLP-1 medicine) Patients currently receiving a GLP-1 through their Part D plan, those with type 2 diabetes, moderate-to-severe obstructive sleep apnea or fatty liver disease are not eligible (a Medicare Part D plan may already cover those conditions).

Patients can talk with their healthcare providers about whether they qualify or refer to https://www.medicare.gov/coverage/weight-loss-drugs.

How can eligible patients get started?
Starting July 1, 2026, eligible patients can begin in five steps:

Talk with a healthcare provider about whether Foundayo or Zepbound is right for them. Request that the provider send a prescription to LillyDirect Pharmacy or a retail pharmacy of their choice. Work with the chosen pharmacy. Ensure that the provider completes a prior authorization. Once approved, the patient pays $50 per month for Foundayo or Zepbound.  LillyDirect can help to determine eligibility and navigate the pre-authorization process. To learn more about eligibility, and see how to get started, visit www.lilly.com/lillydirect/medicare. For questions about Foundayo, Zepbound, or LillyDirect Pharmacy, call 1-844-559-3471.

About Foundayo (orforglipron)
Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day with no planning around food or drink. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About Zepbound (tirzepatide) injection
Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced calorie diet and increased physical activity.

Warnings - Foundayo and Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

About ATTAIN-1 and ATTAIN-2 clinical trial program
The ATTAIN Phase 3 global clinical development program for Foundayo (orforglipron) has enrolled more than 4,500 people with obesity or overweight across two global registration trials.

ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Foundayo 5.5 mg, 9 mg and 17.2 mg as a monotherapy to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes. The trial is the first Phase 3 study of this patient population in which treatment was evaluated as an adjunct to exercise and a balanced, healthy diet rather than a reduced-calorie diet. The trial randomized 3,127 (195 were 65 and older) participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan in 3:3:3:4 ratio to receive either 5.5 mg, 9 mg or 17.2 mg Foundayo or placebo. The primary objective of the study was to demonstrate that Foundayo (5.5 mg, 9 mg or 17.2 mg) is superior to placebo in body weight reduction from baseline after 72 weeks in people with a BMI ≥30.0 kg/m² or a BMI ≥27.0 kg/m² with at least one weight-related comorbidity and a history of at least one self-reported unsuccessful dietary effort to lose body weight.

ATTAIN-2 (NCT05872620) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Foundayo 5.5 mg, 9 mg or 17.2 mg as monotherapy with placebo in adults with obesity or overweight and type 2 diabetes. The trial randomized over 1,613 (418 were 65 and older) participants across the U.S., Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico in a 1:1:1:2 ratio to receive either 5.5 mg, 9 mg or 17.2 mg Foundayo or placebo. The primary objective of the study was to demonstrate that Foundayo (5.5 mg, 9 mg or 17.2 mg) is superior to placebo in mean body weight change from baseline at 72 weeks in people with a BMI ≥27.0 kg/m² and type 2 diabetes who are on stable treatment with either diet/exercise alone or up to three oral antihyperglycemic medications.

In both trials, all participants in the Foundayo treatment arms started the study at a dose of Foundayo 0.8 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5.5 mg (via steps at 0.8 mg and 2.5 mg), 9 mg (via steps at 0.8 mg, 2.5 mg and 5.5 mg) or 17.2 mg (via steps at 0.8 mg, 2.5 mg, 5.5 mg, 9 mg and 14.5 mg). These trials were conducted using an investigational formulation of Foundayo at dosages equivalent to Foundayo tablets.

The post-hoc analysis included in this press release examined efficacy and safety outcomes in subgroups of participants aged <65 and ≥65 years. Efficacy outcomes were analyzed separately for each study; safety data were pooled. The primary endpoint was percent change in body weight from baseline in Week 72.

Limitations
This is a post-hoc, exploratory analysis of data from the ATTAIN-1 and ATTAIN-2 trials. Results are not pre-specified and should be considered hypothesis-generating. The subgroups analyzed (<65 year and ≥65 and) reflect the distribution of participants enrolled in the trials; the number of participants ≥65 is smaller than the <65 subgroup, and formal comparisons between age groups were not pre-specified. These findings will need to be confirmed in dedicated prospective analyses.

About SURMOUNT-1
Throughout the 72-week clinical trial, people who took Zepbound (tirzepatide) sustained weight loss—whether taking the 5 mg, 10 mg or 15 mg dose along with diet and exercise. In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo. Average starting weights were 226.8 lbs for 5 mg, 233.3 lbs for 10 mg, 232.8 lbs for 15 mg, and 231.0 lbs for placebo.

Limitations of the SURMOUNT-1 prespecified subgroup analysis:

This was a prespecified sub‑group analysis among the secondary endpoints of the SURMOUNT‑1 study. This analysis was not adjusted for type I error.

Endnotes and References 
*Terms apply. Eligibility based on Medicare GLP-1 Bridge Clinical Criteria. Prescription required. Talk to your doctor to learn more.
†Ineligible plan types:

Private fee-for-service (PFFS) plans Section 1876 cost contract plans Section 1833 health care prepayment plans (HCPPs) PACE organizations Fallback plans Religious fraternal benefit (RFB) plans Centers for Medicare & Medicaid Services. Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly. Federal Register. December 10, 2024. Available at: https://www.govinfo.gov/content/pkg/FR-2024-12-10/pdf/2024-27939.pdf  Federal Interagency Forum on Aging-Related Statistics. Older Americans: key indicators of well-being. Published May 2024. Accessed February 4, 2026. https://agingstats.gov/docs/LatestReport/Older-Americans-2024-508-May-update.pdf   Based on IQVIA® National Prescription Audit (NPA) Data for both new and refill prescriptions (total) in the U.S. as of 01/10/2025. Data accessed 01/14/2026, representing 94% of prescription data in US. Total prescription volumes and shares for obesity management therapies include Zepbound®, Wegovy®, Saxenda®, Belviq®, Contrave®, Qsymia®, Xenical® and other obesity management medicines. Other product/company names mentioned are the trademarks of their respective owners. Foundayo. Prescribing Information. Lilly USA, LLC. Zepbound. Prescribing Information. Lilly USA, LLC.   Horn DB, et al. Orforglipron for Obesity Treatment in Older Patients ≥65 Years With or Without Type 2 Diabetes. Presented at: European Congress on Obesity (ECO); May 12–15, 2026; Istanbul, Turkey.  Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3)(Incl suppl mat):205-216. doi:10.1056/NEJMoa2206038 Data on File. DOF-ZP-US-0060. Lilly USA, LLC. Medicare GLP-1 Bridge. CMS.gov, Centers for Medicare & Medicaid Services, www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge. Accessed 24 June 2026. INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Foundayo should not be used with other GLP-1 receptor agonist medicines. It is not known if Foundayo is safe and effective for use in children. Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo. Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works. Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. Review these questions with your healthcare provider:

❏ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❏ Do you have a history of diabetic retinopathy?
❏ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❏ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❏ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❏ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

Take Foundayo exactly as your healthcare provider tells you to. Use Foundayo with a reduced-calorie diet and increased physical activity. Take Foundayo by mouth 1 time each day, with or without food. Swallow tablets whole. Do not break, crush, or chew the tablet. If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day. Do not take more than 1 tablet per day. If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment. If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effects that bothers you or don't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound

Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:

❏ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❏ Do you take diabetes medicines, such as insulin or sulfonylureas?
❏ Do you have a history of diabetic retinopathy?
❏ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❏ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❏ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). How to take

Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 25FEB2026

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements 
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including statements about the supply and access of Zepbound (tirzepatide) and Foundayo (orforglipron) as a treatment for adults with obesity or overweight and Foundayo as a treatment for adults with obesity or some adults with overweight who also have weight-related medical problems and reflects Lilly's current belief and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, access, and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that Zepbound or Foundayo will receive additional regulatory approvals, or that Lilly will execute its access and other strategies as planned. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

CMAT-23048 6/2026 ©Lilly USA, LLC 2026. All rights reserved.

SOURCE Eli Lilly and Company

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Roblox To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Roblox between October 30, 2025 and April 30, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

Watch our latest video highlighting the key allegations: https://youtu.be/rFoJC-j0rW0

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Roblox Corporation ("Roblox" or the "Company") (NYSE: RBLX) and reminds investors of the August 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Roblox's organic growth potential; notably, that Roblox would see a significant slowdown in its growth rates as enrollment in the age verification rollout would quickly taper, compounding the resulting slowdown in on-platform communication, resulting in app store rating reductions and a swift reduction in organic growth. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Roblox's securities at artificially inflated prices.

On April 30, 2026, Roblox announced its financial results for the first quarter of fiscal 2026. Management slashed bookings growth guidance down to 8-12% and a corresponding decline to margin expectations. Defendants disclosed the age verification rollout had caused much more significant impacts engagement and organic growth than management had previously suggested and age check adoption had only increased to 51% global daily active users, from 45% at the end of the previous quarter.

Investors and analysts reacted immediately to Roblox's revelation. The price of Roblox's common stock declined dramatically. From a closing market price of $55.26 per share on April 30, 2026, Roblox's stock price fell to $45.13 per share on May 1, 2026, a decline of about 18.33% in the span of just a single day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Roblox's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Verra class action, go to www.faruqilaw.com/RBLX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Roblox Corporation Securities Class Action Lawsuit:

What is the Roblox Corporation securities fraud lawsuit about?
The Roblox Corporation securities fraud lawsuit is a federal securities class action alleging that Roblox Corporation (NYSE: RBLX) and its executives made false and misleading statements to investors by concealing that the Company's age verification rollout would cause a significant slowdown in growth rates, reduce on-platform communication, lead to app store rating reductions, and materially impair Roblox's organic growth potential. As the truth emerged on April 30, 2026 — when Roblox announced Q1 fiscal 2026 results, slashed bookings growth guidance to just 8–12%, disclosed margin deterioration, and revealed that age verification adoption had only reached 51% of global daily active users (up from just 45% the prior quarter), signaling far greater engagement impacts than management had previously suggested — RBLX's stock price fell from $55.26 to $45.13 per share, a decline of approximately 18.33% in a single day, causing significant losses for investors.

Who may be eligible to participate in the Roblox Corporation class action lawsuit?
Investors who purchased or acquired Roblox Corporation (RBLX) securities between October 30, 2025 and April 30, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Roblox securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Roblox employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Roblox Corporation lawsuit?
A lead plaintiff in the Roblox Corporation class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Roblox investor who purchased RBLX securities during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is August 7, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Roblox Corporation stock during the Class Period?
Investors who purchased Roblox Corporation (RBLX) securities between October 30, 2025 and April 30, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Roblox Corporation securities class action is August 7, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/RBLX for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

LCID Deadline: LCID Investors Have Opportunity to Lead Lucid Group, Inc. Securities Fraud Lawsuit PR Newswire NE

On June 25, 2026, Monday.Com Ltd (MNDY) shares fell 5.4% today, currently priced at $67.05. This decline reflects a broader trend, with the stock down 54.5% yea

, /PRNewswire/ -- Pabrai Wagons Advisors, an investment adviser and ETF sponsor, today announced exchange listing changes for the Pabrai Wagons ETF (WAGN) from the New York Stock Exchange ("NYSE") to the New York Stock Exchange ARCA, Inc ("NYSE ARCA").

No shareholder action is expected because of this change, nor is the transfer expected to affect the trading of fund shares. NYSE ARCA is the primary listing venue for most U.S.-listed ETFs, and its ETF listing requirements better align with how the Pabrai Wagons ETF is managed.

The changes are set forth below and are anticipated to go into effect after markets open on June 30, 2026.

Fund Name

Ticker

Current Exchange

New Exchange

Pabrai Wagons ETF

WAGN

NYSE

NYSE ARCA

About Pabrai Wagons Advisors:

Dhandho Funds LLC, dba Pabrai Wagons Advisors, is an SEC registered investment adviser. To learn more about the company, please visit DhandhoFunds.com.

Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the Pabrai Wagons ETF, please call 1-800-501-1792 or visit the website at www.WagonsETF.com. Read the prospectus or summary prospectus carefully before investing.

Investing involves risk, including the possible loss of principal. For a complete discussion of the risks associated with the Pabrai Wagons ETF, please refer to the prospectus.

Pabrai Wagons Advisors serves as the investment adviser. WAGN is distributed by Quasar Distributors, LLC.

Media Contact: Aidan Townsend, [email protected]

SOURCE Dhandho Funds LLC, dba Pabrai Wagons Advisors

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Commvault To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Commvault between April 29, 2025 and January 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Commvault Systems, Inc. ("Commvault" or the "Company") (NASDAQ: CVLT) and reminds investors of the July 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Defendants provided investors with material information pertaining to Commvault's projected ARR growth for fiscal year 2026. Defendants' statements included, among other things, misleading guidance and projections related to the Company's new net ARR growth. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Commvault's ARR growth environment; pertinently, Commvault knew or recklessly disregarded that the Company's ARR growth guidance failed to properly factor in crucial variables, such as the type of sale. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Commvault's securities at artificially inflated prices.

On January 27, 2026, Commvault reported financial results for the third quarter of fiscal 2026 ended December 31, 2025, including "40% growth in SaaS ARR to $364 million," as noted by the Company's Chief Accounting Officer ("CAO") during the earnings call to discuss these results. Additionally, the CAO said "60% of our deals actually closed in the last few weeks of the quarter." According to Bloomberg Intelligence, "SaaS ARR growth of 40% represents a meaningful deceleration from 56%" reported for the second quarter fiscal 2026.

Following this news, Commvault stock declined over 31% on January 27, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Commvault's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Commvault class action, go to www.faruqilaw.com/CVLT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Commvault Systems Securities Class Action Lawsuit:

What is the Commvault Systems securities fraud lawsuit about?

The Commvault Systems securities fraud lawsuit is a federal securities class action alleging that Commvault Systems, Inc. (NASDAQ: CVLT) and its executives made false and misleading statements to investors by providing materially misleading guidance and projections related to the Company's annual recurring revenue (ARR) growth while concealing that its ARR growth guidance failed to properly account for crucial variables — such as the type of sale — that significantly affected the Company's true growth trajectory. As the truth emerged on January 27, 2026, when Commvault reported Q3 fiscal 2026 results showing SaaS ARR growth of only 40% — a meaningful deceleration from 56% in the prior quarter — CVLT's stock price fell over 31% in a single day, causing significant losses for investors.

Who may be eligible to participate in the Commvault Systems class action lawsuit?

Investors who purchased or acquired Commvault Systems (CVLT) stock between April 29, 2025 and January 26, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Commvault securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Commvault employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Commvault Systems lawsuit?

A lead plaintiff in the Commvault Systems class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Commvault investor who purchased CVLT stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 17, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Commvault Systems stock during the Class Period?

Investors who purchased Commvault Systems (CVLT) stock between April 29, 2025 and January 26, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Commvault Systems securities class action is July 17, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/CVLT for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AeroVironment, Inc. ("AeroVironment" or the "Company") (NASDAQ: AVAV) and certain officers. The class action, filed in the United States District Court for the Eastern District of Virginia, and docketed under 26-cv-01429, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AeroVironment securities between June 25, 2025 and March 10, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired AeroVironment securities during the Class Period, you have until July 27, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

AeroVironment operates as a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber.

On May 1, 2025, AeroVironment announced it had completed the acquisition of BlueHalo, LLC ("BlueHalo"), a defense technology firm specializing in advanced engineering products, in an all-stock transaction with an enterprise value of approximately $4.1 billion.

Three years earlier, BlueHalo had been awarded a $1.4 billion contract to deliver BADGER phased array antenna systems (a type of advanced ground-terminal system used to track satellites), to support the United States Space Force's Satellite Communication Augmentation Resource ("SCAR") program. The BADGER would be a bespoke product designed for the United States ("U.S.") Space Force, according to its specifications. This contract value subsequently increased to $1.7 billion.

The SCAR program represents the U.S. Space Force's efforts to modernize antennas used by the Satellite Control Network ("SCN"), which is comprised of 19 fixed antennas across the world and executes tasks such as tracking satellites, transmitting signals, and conducting telemetry, or accessing data from satellites to assess their status and health.

In an April 2023 report, the U.S. Government Accountability Office described the SCN as "aging and difficult to maintain." The U.S. Space Force has described the purpose of the SCAR program as modernizing the aging SCN by introducing phased array antennas to the network that boast newer capabilities, such as the ability to communicate with more than one satellite simultaneously.

During the Class Period, Defendants consistently assured investors that the SCAR program would drive revenue growth for AeroVironment moving forward. Among other items, Defendants stated that the SCAR program represented a "tremendous growth opportunity," that AeroVironment's work pursuant to the contract was "very much on track," that the customer was "asking for more [BADGER systems]," and that the Company stood "ready to build more."

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the SCAR program and the U.S. Space Force's ongoing efforts to modernize the SCN; (ii) accordingly, Defendants overstated AeroVironment's business and financial prospects; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On January 20, 2026, AeroVironment announced that the U.S. government had issued a stop work order on the Company's agreement to deliver BADGER systems to the SCAR program. In the same announcement, AeroVironment stated that the stop work order "allows for the parties to negotiate an amended agreement for the future of the SCAR program" and that "[t]he Company expects to continue to deliver capabilities and products for the SCAR program."

On this news, AeroVironment's stock price fell $61.97 per share, or 15.77%, to close at $330.89 per share on January 20, 2026.

Then, on March 2, 2026, Space News reported that the U.S. Space Force was reopening the SCAR program and "reassessing how to move forward." Space News quoted Colonel Owen Stevens, director of contracting at the Space Rapid Capabilities Office, which supervised SCAR, as stating, "We have been in conversations with the [senior acquisition executive] for a little while now, and we are going to move into a new acquisition strategy for SCAR."

On this news, AeroVironment's stock price fell $43.93 per share, or 17.42%, to close at $208.32 per share on March 2, 2026.

Then, on March 10, 2026, AeroVironment announced its financial results for the third quarter of fiscal year 2026. Among other items, AeroVironment reported a third-quarter operating loss of $179.0 million, compared to an operating loss of $3.1 million for the same period in fiscal year 2025. These financial results reflected the impact of a $151.3 million goodwill impairment in the Company's space division after the stop work order on the Company's BADGER systems built for the SCAR program. AeroVironment also reported that the U.S. Space Force had terminated the Company's contract concerning the SCAR program, and as a result, it would have to "recompete" for the SCAR program.

On this news, AeroVironment's stock price fell $13.84 per share, or 6.24%, to close at $207.73 per share on March 11, 2026.

On March 31, 2026, the U.S. Space Force announced its decision to diversify suppliers and rely on less costly commercial, off-the-shelf solutions in connection with its work to upgrade the SCN, instead of pursuing another single-vendor bespoke solution.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

On June 25, 2026, Haemonetics Corp (HAE) shares rose 6.5% today, bringing the current price to $77.62. The stock has experienced a 52-week range between $47.32

On June 25, 2026, Helmerich and Payne Inc (HP) shares rose 3.8% to a current price of $34.01. The stock has experienced a 52-week range of $15.08 to $41.82, refle

Shareholder Alert: Ademi LLP investigates whether Synaptics Incorporated is obtaining a Fair Price for Public Shareholders PR N